177Lutetium-Octeotrate May Be Practice-Changing for Advanced Pancreatic Neuroendocrine Tumors
177Lutetium-octreotate can improve progression-free survival vs sunitinib in patients with progressive pancreatic neuroendocrine tumors.
177Lutetium-octreotate can improve progression-free survival vs sunitinib in patients with progressive pancreatic neuroendocrine tumors.
Preoperative FDG-PET may predict pathologic response to neoadjuvant therapy for borderline resectable/locally advanced PDAC.
SY-5609 is currently being evaluated in combination with chemotherapy in a phase 1 trial.
Adjuvant mFOLFIRINOX improved disease-free survival, cancer-specific survival, and overall survival at 5 years.
Researchers found that 30% of pancreatic adenocarcinoma trials completed from 2010 through 2020 did not have results available.
Men tend to have a higher risk of cancer than women, and factors such as smoking, alcohol use, and diet do not appear to explain this disparity.
In a cohort of privately-insured patients, the median out-of-pocket cost for genetic counseling was $0.
Modified FOLFIRINOX represents a reference regimen for patients with borderline resectable pancreatic ductal adenocarcinoma, according to researchers.
Counties in the Southeastern United States primarily accounted for the highest 5% of mortality rates for gastric, pancreatic, and colorectal cancer.
The median survival was 9.8 years for patients with screen-detected PDAC and 1.5 years for those with PDAC detected outside of surveillance.